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3-Methylglutaconic aciduria type I is an autosomal recessive disorder clinically characterized by various symptoms
ranging from delayed speech development to severe neurological handicap. This disorder is caused by a deficiency
of 3-methylglutaconyl-CoA hydratase, one of the key enzymes of leucine degradation. This results in elevated
urinary levels of 3-methylglutaconic acid, 3-methylglutaric acid, and 3-hydroxyisovaleric acid. By heterologous
expression in Escherichia coli, we show that 3-methylglutaconyl-CoA hydratase is encoded by the AUH gene, whose
product had been reported elsewhere as an AU-specific RNA-binding protein. Mutation analysis of AUH in two
patients revealed a nonsense mutation (R197X) and a splice-site mutation (IVS8-1GrA), demonstrating that mu-
tations in AUH cause 3-methylglutaconic aciduria type I.
3-Methylglutaconic aciduria is a group of metabolic dis-
orders characterized by increased urinary excretion of
3-methylglutaconic acid and 3-methylglutaric acid. At
present, four distinct forms have been recognized. Type
I (MIM 250950) represents the isolated 3-methylgluta-
conyl-CoA hydratase deficiency. This mitochondrial en-
zyme catalyzes the fifth step in leucine catabolism, as
shown in figure 1, which is the conversion of 3-meth-
ylglutaconyl-CoA to 3-hydroxy-3-methylglutaryl-CoA
(HMG-CoA). Type II (MIM 302060), also referred to
as Barth syndrome, is an X-linked mitochondrial car-
diomyopathy associated with neutropenia and growth
retardation and caused by mutations in the gene encod-
ing tafazzin (TAZ). Type III (MIM 258501) or Costeff
syndrome, is an autosomal recessive disorder caused by
mutations in the OPA3 gene, which lead to bilateral
optic atrophy. Type IV or “unspecified” 3-methylglu-
taconic aciduria (MIM 250951) comprises a heteroge-
neous group of patients with progressive neurological
symptoms. The hydratase activity in Barth syndrome,
Costeff syndrome, and type IV 3-methylglutaconic acid-
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uria is normal, and the excretion of 3-methylglutaconic
acid and 3-methylglutaric acid is secondary. Among the
four types, patients with type I excrete the highest levels
of 3-methylglutaconic acid and 3-methylglutaric acid.
Furthermore, these patients additionally excrete in-
creased amounts of 3-hydroxyisovaleric acid; therefore,
3-hydroxyisovaleric acid is an important parameter for
differentiation between the isolated 3-methylglutaconyl-
CoA hydratase deficiency and the other types. The phe-
notypic presentation of 3-methylglutaconyl-CoA hydra-
tase deficiency varies from mild, including delayed
speech development and hyperchloremic acidosis asso-
ciated with gastroesophageal reflux, to a much more
severe phenotype, including seizures and cerebellar ab-
normalities. Although the hydratase was purified par-
tially in the late 1950s (Hilz et al. 1958), the gene en-
coding the protein had not been identified.
Several mitochondrial enzymes with enoyl-CoA hy-
dratase activity have been characterized. The first one,
called “crotonase,” is most active toward short-chain
enoyl-CoAs and participates in the b-oxidation of short-
chain fatty acids. Studies performed by Hilz et al. (1958)
showed that an enzyme other than crotonase is respon-
sible for the hydratase step in the degradation of leucine.
Indeed, our preliminary studies showed that crotonase
is not active with HMG-CoA when measured in the
reverse direction. A second enzyme harboring hydratase
activity is mitochondrial trifunctional protein (MTP),
which also catalyzes dehydrogenation and thiolytic
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Figure 1 The metabolic pathway of L-leucine. The different en-
zymes involved are numbered as follows: 1, Branched-chain amino
acid transaminase; 2, Branched-chain 2-keto acid dehydrogenase com-
plex; 3, Isovaleryl-coa dehydrogenase; 4, Methylcrotonyl-CoA car-
boxylase; 5, 3-Methylglutaconyl-CoA hydratase; and 6, 3-Hydroxy-
3-methylglutaryl-CoA lyase.
Figure 2 Expression and purification of MBP-AUH fusion pro-
tein in E. coli. Total E. coli extract (T) and affinity-purified fusion
protein (P) were analyzed by 10% SDS-PAGE and stained with Coom-
assie brilliant blue.
cleavage of long-chain fatty acids. Together with very-
long-chain acyl-CoA dehydrogenase, this protein is the
main enzyme in the long-chain fatty acid b-oxidation.
It is unlikely, however, that this enzyme is involved in
the degradation of leucine, because patients with MTP
deficiency (MIM 143450, MIM 600890) have no ab-
normal urinary excretion of 3-methylglutaconic acid.
Nakagawa et al. (1995) purified an AU-specific RNA-
binding protein, designated “AUH” (GenBank accession
numbers NM_001698 and NT_008476), using an af-
finity column displaying AU-rich elements. The protein
contained a hydratase motif and shared 32% sequence
identity with crotonase. The enoyl-CoA hydratase ac-
tivity with butenoyl-CoA (C4:1-CoA) as substrate was
a thousandfold lower when compared with crotonase.
The three-dimensional structure of human AUH has
been determined at 2.2-A˚ resolution and predicted a high
affinity for short-chain substrates (Kurimoto et al.
2001).
To investigate whether AUH has 3-methylglutaconyl-
CoA hydratase activity, we expressed AUH as a fusion
protein with maltose-binding protein (MBP). The ORF
of AUH was amplified from human cDNA by use of the
primers 3AUHfEcoRI (5′-ATA TGA ATT CAA CAT
GGC GGC CGC GGT GG-3′) and 1097AUHrXbaI (5′-
ATA TTC TAG ACA TAT AGT GGA TCC GAA AGA
C-3′), digested with EcoRI and XbaI, and subsequently
cloned into the EcoRI and XbaI restriction sites of the
pMAL-C2X vector (New England Biolabs). The cloned
PCR products were sequenced to assess the integrity of
the PCR process. Next, the MBP-AUH was expressed
in Escherichia coli and affinity-purified to homogeneity
according to the manufacturer’s protocol (fig. 2).
The 3-methylglutaconyl-CoA hydratase activity of the
expressed protein was measured in the reverse direction,
using HMG-CoA as substrate. The reaction mixture
contained 50 mM Tris pH 7.4, 10 mM EDTA, 1 mg/ml
BSA, and 0.1 mM HMG-CoA and was started by ad-
dition of purified protein. The formation of 3-methyl-
glutaconyl-CoA was followed spectrophotometrically at
260 nm using a molar extinction coefficient of 6200 L/
mol/cm. The short-chain enoyl-CoA hydratase activity
was measured using butenoyl-CoA as a substrate as de-
scribed by Wanders et al. (1992). For comparison, both
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Figure 3 Mutation analysis of AUH in two patients. A, PCR
fragment B amplified from cDNA of two control subjects (C1 and C2)
and patient 1 (P) showing the 42-bp deletion (exon 9) as a consequence
of a IVS8-1GrA mutation. B, PCR-RFLP analysis of the 589CrT
mutation. Part of intron 5 and exon 5 containing the c.589CrT mu-
tation was amplified using a mismatch primer (558AUHfNdeI 5′-TGG
CTT TAG CCT GTG ACA TA-3′) creating an NdeI restriction site in
the 589T allele. For convenient control of the restriction, the reverse
primer (In5AUHrM13NdeI 5′-cag gaa aca gct atg acc CAT ATG ACC
ATT AGG ACC AAC AAG TG-3′) contained an M13 extension and
a second NdeI restriction site. PCR products from genomic DNA of
a control subject (C) and patient 2 (P) were loaded directly () or
digested with NdeI () before electrophoresis.
Table 1
Hydratase Activity Measurements of AUH and Crotonase with
HMG-CoA and Butenoyl-CoA (C4:1-CoA) as Substrate
Hydratase Activity
MBP-AUH
(nmol/min/mg)
Bovine Liver
Crotonase
(nmol/min/mg)
HMG-CoA 110 !1
C4:1-CoA 4.8 8.3 #105
Ratio HMG-CoA/C4:1-CoA 23 !106
activities were also measured using bovine liver croton-
ase obtained from Sigma.
As reported above for AUH, we also found very low
hydratase activity with C4:1-CoA. In addition, we
found that AUH has high 3-methylglutaconyl-CoA hy-
dratase activity. Indeed, the HMG/C4:1 activity ratio
was 120. In contrast, crotonase has no detectable 3-
methylglutaconyl-CoA hydratase activity (table 1).
Therefore, AUH is a strong candidate for the underlying
enzymatic defect of 3-methylglutaconic aciduria type I.
To date, eight patients have been described with iso-
lated 3-methylglutaconyl-CoA hydratase deficiency
(Duran et al. 1982; Narisawa et al. 1986; Gibson et al.
1992; Gibson et al. 1998; Shoji et al. 1999; Ensenauer
et al. 2000). The hydratase deficiency in these patients
has been determined by use of an overall enzyme assay
measuring three steps of leucine degradation, from 3-
methylcrotonyl-CoA to acetoacetic acid (Narisawa et al.
1989). We reinvestigated fibroblasts from two patients
(Duran et al. 1982; Ensenauer et al. 2000) with our novel
enzyme assay, using the same conditions as described
above, but the reaction was started with 0.3 mg/ml fi-
broblast homogenate. The reaction mixture was incu-
bated for 30 min at 37C, stopped with 0.2 M hydro-
chloric acid, and subsequently neutralized with sodium
hydroxide. Formation of 3-methylglutaconyl-CoA was
quantified on HPLC using a reverse-phase C18 column
(Supelcosil LC-18-DB, 250 mm # 10 mm, 5 mm, Su-
pelco). Separation of the acyl-CoAs was achieved by
elution with a linear gradient of methanol (10%–37.6%
in 22 min) in potassium phosphate buffer (50 mM, pH
5.3). Both patients showed clear deficiency of 3-methyl-
glutaconyl-CoA hydratase (patients !0.1; control sub-
jects nmol/min/mg protein), whereas the cro-2.8 0.6
tonase activity was normal for both patients.
To determine whether 3-methylglutaconic aciduria type
I is caused by mutations in AUH, the ORF of AUH was
amplified from human cDNA in two overlapping frag-
ments, using the followingM13-tagged primers: fragment
A: 28AUHf-21M13 (5′-tgt aaa acg acg gcc agt TCG
CAG GTC CAC GCC GTA AAC-3′) and 680AUHrM13
(5′-cag gaa aca gct atg acc CGC GTG GCA ATC GCT
GTG TC-3′); fragment B: 505AUHf-21M13 (5′-tgt aaa
acg acg gcc agt GCT ATT CTT CCA GTG CCA AC-3′)
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and 1097AUHrM13 (5′-cag gaa aca gct atg acc CATATA
GTG GAT CCG AAA GAC-3′). PCR fragments obtained
from patients and two control subjects were sequenced
with Big Dye Terminators and were analyzed on an
Applied Biosystems 377A automated DNA sequencer,
following the manufacturer’s protocols (PE Applied
Biosystems).
The first patient, the third son of consanguineous par-
ents, of Afghan origin, had retardation in speech devel-
opment. A delayed motor development became evident
in retrospect (Ensenauer et al. 2000). The amplification
product of fragment B was ∼50 bp smaller than that
found in controls (fig. 3A). Sequence analysis revealed
that this was caused by skipping of exon 9. The splice
acceptor and donor site neighboring exon 9 conform to
the AG/GT rule. To identify the underlying mutation
causing missplicing, we amplified splice sites flanking
exon 9 from genomic DNA, using the following primers:
In8AUHf-21M13 (5′-tgt aaa acg acg gcc agt GAC ATG
CCT CTT TGA AGC AC-3′) and In9AUHrM13 (5′- cag
gaa aca gct atg acc GCA AGG GTA ATC TTG CTC
AG-3′). In patient 1, we identified a homozygous IVS8-
1GrA mutation, which disrupts the consensus sequence
of the splice acceptor site. Exon 9 encodes a-helix H9
(Kurimoto et al. 2001), which crystal structure analysis
suggests to be a constituent of the active-site pocket and
is also necessary for subunit interaction and trimer
stability.
The second patient is the younger of two affected
brothers of healthy nonconsanguineous Moroccan par-
ents. He had no physical abnormalities; only his speech
development was retarded (Duran et al. 1982). Sequence
analysis at the cDNA level showed an apparently ho-
mozygous nonsense mutation, 589CrT. PCR-RFLP
analysis on genomic DNA showed heterozygosity for the
589CrT mutation (fig. 3B), indicating that the other
allele is a null allele or produces an unstable mRNA.
The R197X nonsense mutation causes the translation to
be terminated before glutamate 209, which together
with glutamate 189 forms the catalytic group of the
active-site pocket. In conclusion, our data show that
mutations in AUH cause 3-methylglutaconic aciduria
type I.
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